The Effect of Combination of Dapagliflozin and Sildenafil in Treatment of Heart Failure Patients With Secondary Pulmonary Hypertension

Fayoum University

Status

Completed

Conditions

Heart Failure NYHA Class II

Treatments

Drug: Sildenafil

Drug: Dapagliflozin (DAPA)

Study type

Interventional

Funder types

Other

Identifiers

NCT06778330

M 722

Details and patient eligibility

About

This study aims to determine the efficacy of sildenafil (improve PAH) as an add-on therapy to dapagliflozin in the treatment of heart failure patients with secondary pulmonary arterial hypertension and compare the result with monotherapy dapagliflozin

Enrollment

100 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

patients with established heart failure with secondary pulmonary hypertension seen by a primary care provider to diagnose a heart disease, the patient's symptoms which may experience:

Dizziness or fainting
Heart palpitations, which may feel like your heart fluttering or skipping beats
Shortness of breath

Exclusion criteria

Patients with a history of severe allergic reactions or hypersensitivity to sildenafil, dapagliflozin, or related medications.
Individuals with contraindications to the use of sildenafil or dapagliflozin.
Patients with pulmonary arterial hypertension (PAH) due to conditions other than heart failure (e.g., idiopathic PAH).
severe hepatic impairment
aged less than 18 years.
valvular heart disease .
Patients with a known or suspected history of non-compliance with medical treatment or inability to adhere to study procedures.
life expectancy of less than 6 months .
Pregnant or breastfeeding women